Cytosorbents (NASDAQ:CTSO) Announces Earnings Results

Cytosorbents (NASDAQ:CTSO) announced its quarterly earnings data on Thursday. The medical research company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.42, FiscalAI reports. The business had revenue of $9.73 million during the quarter, compared to analysts’ expectations of $9.90 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%.

Here are the key takeaways from Cytosorbents’ conference call:

• CytoSorbents reported third-quarter operating cash flow of about $43,000, excluding restructuring payments, meeting its stated breakeven objective. Product gross margin rose to 75% and adjusted EBITDA loss narrowed to about $284,000, though management cautioned that cash flow may fluctuate and breakeven is not guaranteed every quarter.
• Revenue increased 3% year over year to $9.7 million, with distributor and partner sales up 18%, but sales in Germany fell about 20%–21% amid reduced sales-force coverage. The company has begun rebuilding its German team and plans further hires, while targeting sustainable product gross margins in the mid-70% range.
• The company is preparing an expanded DrugSorb-ATR De Novo submission for ticagrelor use in early 2027, pending completion of an animal study and further regulatory work; it also expects a separate DOAC pathway submission in 2027. Management cited encouraging clinical evidence and FDA discussions, but U.S. authorization and timing remain uncertain.
• CytoSorbents is exploring non-dilutive funding, partnerships, licensing, and other strategic options for HemoDefend-BGA, a blood-product filtration technology, aiming to unlock value without significant investment from core operations. No specific deal or funding outcome was announced.
• The company ended the quarter with $5.7 million in cash, cash equivalents, and restricted cash, and said it is working to meet its remaining Nasdaq listing requirement and restructure its debt by year-end. Its ability to complete those efforts and finance the business remains uncertain.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO traded up $0.03 during trading on Thursday, hitting $5.37. 6,307 shares of the stock traded hands, compared to its average volume of 14,510. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. The company has a market cap of $16.92 million, a price-to-earnings ratio of -0.93 and a beta of 1.49. The company has a fifty day moving average price of $4.96 and a two-hundred day moving average price of $9.15. Cytosorbents has a 52-week low of $2.84 and a 52-week high of $17.00.

Analysts Set New Price Targets

Several research analysts recently issued reports on CTSO shares. WBB Securities assumed coverage on shares of Cytosorbents in a report on Wednesday, October 21st. They set a “speculative buy” rating and a $9.50 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cytosorbents currently has an average rating of “Hold” and an average target price of $74.83.

Insider Transactions at Cytosorbents

In other news, CEO Phillip Chan purchased 200,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were bought at an average price of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer owned 1,944,432 shares in the company, valued at $680,551.20. This represents a 11.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 7.80% of the company’s stock.

About Cytosorbents

CytoSorbents Corporation is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment. The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications.